Rizmoic (naldemedine)
- Region
- 🇪🇺 EU
- Active substance
- naldemedine
- Company
- Shionogi B.V.
- Status
- Authorised
- Therapeutic area
- Constipation
- CHMP opinion
- Thu 13 Dec 2018
- EU approval
- Mon 18 Feb 2019
- Application
- EMEA/H/C/004256
- ATC
- A06AH05
- Official record
- www.ema.europa.eu
Indication
Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
Regulatory milestones
No milestones recorded in the last year.
Follow Rizmoic
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.